



Introduction: Metabolic syndrome (MetS) is a multifactorial disorder in which dyslipidemia plays an important role. Fatty acid-binding protein 2 
(FABP 2) is responsible for transport of free fatty acids in the intestinal endothelium cells. FABP2-genetic variants might aff ect plasma lipid con-
centrations and intracellular lipid transport. The aim of this study was to investigate the association between FABP2 Ala54Thr genetic polymorphism 
and metabolic syndrome and some biochemical and anthropological parameters in elderly subjects.
Materials and methods: This cross-sectional study included 140 men and 176 women older than 70 years. Fasting serum concentration of glu-
cose, lipid parameters, total proteins and C-reactive protein were determined by standardized methods. Presence (MetS(+)) or absence (MetS(-)) 
of MetS was determined according to criteria of the International Diabetes Federation. FABP2 genetic polymorphism Ala54Thr (rs1799883) was 
genotyped with PCR-RFPL.
Results: The genotype frequencies for Ala/Ala, Ala/Thr and Thr/Thr genotype were 60, 36 and 6 in MetS(-), and 131, 70 and 13 in MetS(+), respec-
tively, without statistical signifi cance (P = 0.567). Ala/Ala genotype was a subgroup of non-carriers, while Ala/Thr and Thr/Thr genotypes were 
Thr54-carriers. Median triglyceride concentration was signifi cantly lower in carriers then in non-carriers for whole MetS(+) group (P = 0.050); the-
re were no signifi cant diff erence between men with MetS (P = 0.144), but there was a diff erence between women with MetS (P = 0.020). T-test 
showed that mean HDL cholesterol concentrations in MetS(+) group for Thr54-carriers was signifi cantly higher in whole group (P = 0.001), and for 
both genders (men P = 0.039; women P = 0.004) as compared to non-carriers.
Conclusions: FABP2 genetic polymorphism is associated with lower triglyceride and higher HDL-cholesterol concentrations in elderly subjects 
with MetS. This genetic variation might be a useful marker for understanding dyslipidemia in MetS.
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Metabolic syndrome (MetS) has become a global 
health concern over the past few decades, world-
wide (1-3). General risk factors for developing MetS 
are abdominal obesity, hypertension, hyperglyce-
mia and dyslipidemia. In addition to these, the 
characteristics of MetS include proinfl ammatory 
and prothrombotic state, hyperuricemia and gout, 
microalbuminuria, and electrolyte disbalance 
(2,4-6).
Many genetic polymorphisms might be involved 
in the pathogenesis of MetS (7). The genes respon-
sible for the metabolism and transport of lipids, 
regulation of arterial blood pressure, the transport, 
regulation and metabolism of glucose, hormonal 
regulation and other factors might contribute to 
the development of MetS (7-9).
The fatty acid-binding proteins (FABPs) are mem-
bers of the superfamily of small (14-15 kDa) intra-
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cellular lipid-binding proteins (LBPs) (10). LBPs play 
various important roles in signaling, regulation, 
membrane traffi  cking, immune response, lipid me-
tabolism and transport (11). Intestinal fatty acid-
binding protein (I-FABP or FABP2) is one of nine 
diff erent FABPs identifi ed in mammals, besides liv-
er, heart and muscle, adipocyte, epidermal, ileal, 
brain, myelin and testis FABP (10,12). The primary 
function of all FABPs is the regulation of fatty acid 
uptake (FA) and intracellular transport.
The genes that encode FABPs are dispersed 
throughout the genome and their structure is well 
conserved (13). Each gene consists of four exons 
separated by three introns of variable sizes (13). 
The FABP2 gene encodes for intestinal fatty acid-
binding protein, which is involved in the uptake, 
intracellular metabolism, and/or transport of long 
chain fatty acids (13). The gene consists of 3382 
nucleotides located in the chromosomal region 
4q28-4q31, arranged in four exons containing 
~700 bp and three introns containing ~2650 bp 
(14,15). I-FABP (FABP2) protein consists of 131 ami-
no acid residues and has a high content of β-strand 
structure. The internal binding cavity is capable of 
binding one molecule of ligand, with affi  nity de-
pending on fatty acid identity (14). I-FABP (FABP2) 
has two forms (alanine-containing (A54) or threo-
nine-containing (T54) protein which display diff er-
ences in binding and transporting fatty acids 
across cells (16). Polymorphism is due to the transi-
tion from G to A at codon 54 of the FABP2 gene 
and results in a substitution of alanine by threo-
nine (Ala54Thr) in exon 2 (rs1799883). Threonine-
containing protein has greater ability to transport 
long chain fatty acids than alanine-containing pro-
tein (16). The Ala54Thr polymorphism of the fatty 
acid-binding protein 2 gene can be commonly 
found in around 30% of the most populations and 
is associated with insulin resistance (17), dyslipi-
demia and obesity (18,19), which are all cardinal 
components of MetS. Three diff erent meta-analy-
ses evaluated the eff ects of the Ala54Thr polymor-
phism on body mass index (BMI) (20), insulin resis-
tance (21) and fasting lipids (18) in diff erent world 
populations. The fi rst analysis showed that there is 
no association between Ala54Thr polymorphism 
and BMI (20). However, weak association appears 
to be present between this polymorphism and in-
sulin resistance (21). Finally, strong association was 
found between the Thr54 allele and higher levels 
of triglycerides (TGs) and LDL-cholesterol, and low-
er levels of HDL-cholesterol (18).
As FABP2 is involved in the transport of fatty acids 
inside intestinal cells and therefore might aff ect 
the fatty acids composition of chylomicron triglyc-
erides, we hypothesized that this polymorphism 
might be involved in the pathogenesis of MetS at 
least as its dyslipidemic component.
The aim of this study was to investigate the asso-
ciation between FABP2 Ala54Thr genetic polymor-
phism and metabolic syndrome and some bio-




This is a cross-sectional and comparative study, the 
fi nal step of a large longitudinal national multi-
center epidemiological study of chronic diseases 
in Croatian population, conducted by the research-
ers and medical team from the Institute for Medi-
cal Research and Occupational Health and their 
collaborators. Study design was already described 
in details elsewhere (22,23). In short, the cohort 
was established in 1969, with 3 follow-ups. The last 
one dates from 2006/2007 when participants were 
over 70 years old. Only free-living participants, 
able to look after themselves and manage their 
everyday activities were included in the study. The 
study involved 345 elderly participants among 
whom the prevalence of MetS was investigated. 
Of these, 316 participants had enough blood sam-
ple volumes for all biochemical analyses, DNA iso-
lation and genetic testing. With regard to the pres-
ence or absence of MetS according to the criteria 
of the International Diabetes Federation (IDF) (24), 
subjects were divided into two subgroups, MetS(+) 
and MetS(-). MetS(+) criteria was satisfi ed if waist 
circumference was ≥ 94 cm for men or ≥ 80 cm for 
women plus any of two following criteria: fasting 
glucose ≥ 5.6 mmol/L (or previously diagnosed 
adult diabetes mellitus and antidiabetic therapy), 
triglycerides ≥ 1.7 mmol/L, HDL-cholesterol < 1.03 
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mmol/L for men or < 1.29 mmol/L for women, and 
blood pressure ≥ 130/85 mmHg.
All participants signed the informed consent form 
and the study was approved by the Institute’s Eth-
ics Committee.
Subjects
The study included 140 men and 176 women 
whose median age was 78 (range 71-93 years) and 
77 (range 71-92 years), respectively. Blood sam-
pling, medical examination and interviews were 
performed between 07.00 and 12.00 a.m. Height, 
weight and waist circumference were measured 
according to the International Biological Program 
Protocol (25). Waist circumference was taken on 
midway between the 10th rib and the top of the 
iliac crest (at the level of the umbilicus) using a fl ex-
ible nonstretchable plastic tape and was approxi-
mated to the nearest 0.1 cm. Blood pressure was 
measured in the sitting position after 10-20 min 
rest using a mercury sphygmomanometer (Reister, 
Jungingen, Germany). Hypertension was defi ned 
as blood pressure ≥ 130/85 mmHg. Mean arterial 
pressure (MAP) was calculated according to equa-
tion: MAP = [(2 x diastolic) + systolic] / 3 (26). Body 
mass index (BMI) was calculated according to the 
formula: mass (kg) / body height (m)2. Smoking 
status was defi ned in line with the questionnaire 
data: smokers were defi ned as all ex-smokers and 
active smokers, whereas non-smokers were those 
that had never smoked.
Blood sampling
Blood samples were collected in the K2EDTA tubes 
and serum separator tubes (BD Vacutainer, Becton 
Dickinson, Plymouth, UK) by puncture from an an-
tecubital vein after an overnight fasting. Serum 
samples were stored at -20°C until analyses.
Methods
Serum concentration of glucose, total proteins and 
C-reactive protein (CRP) were determined by stan-
dardized methods on Beckman Coulter AU400 se-
lective autoanalyzer (Beckman Coulter, Tokyo, Ja-
pan) using reagents from the same manufacturer 
(Beckman Coulter, Hamburg, Germany). Lipid pa-
rameters (total cholesterol, HDL-cholesterol and 
triglycerides) were determined with enzymatic 
methods on the Roche COBAS MIRA autoanalyzer 
using reagents from Boehringer-Manheim Diag-
nostics and Hoff mann-La Roche (Roche diagnos-
tics, Mannheim, Germany). LDL-cholesterol was 
calculated according to the Friedwald formula 
(27).
DNA was extracted from whole blood by automa-
tized salting out method with a Biosprint 15 DNA-
Blood Kit (Qiagen GmbH, Hilden, Germany) on a 
KingFisher automatic system (Thermo Labsystems, 
Helsinki, Finland). FABP2 genetic polymorphism 
(2445G→A) Ala54Thr was genotyped with PCR-RF-
PL method (28), using Hha I restriction endonu-
clease (Fermentas International Inc., Burlington, 
Canada). Polymerase chain reactions of exon 2 
were performed with primers (Sigma-Aldrich 
Chimie GmbH, Taufkirchen, Germany), whose se-
quence was previously described (28). The reac-
tions were performed in Eppendorf Mastercycler 
3350 (Eppendorf, Hamburg, Germany) using 500 
ng of genomic DNA, 7.5 x 10-3 of each primer, 15 
mM MgCl2 in buff er, 10 nmol of each dNTP and 0.6 
U of Fast start TaqDNA-polymerase (Roche, Man-
heim, Germany) in 25 µl of reaction mixture. Each 
of 30 cycles consisted of 30 seconds (s) at 94 °C, 45 
s at 58 °C, and 45 s at 72 °C, followed by a 5-min 
extension at 72 °C. 6 µl of PCR-products were di-
gested by 12 U of Hha I restriction endonuclease 
(Fermentas, Burlington, Canada) at 37 °C for 16 
hours. 180-bp fragments were cleaved into 99-and 
81-bp fragments (Ala54) or were undigested 
(Thr54). Fragments were visualized on 3%-agarose 
gel with ethidium bromide.
Statistical analysis
Statistical data analysis was performed using SPSS 
for Windows 20.0 (Chicago IL USA). Categorical 
variables were compared using Pearson’s χ2-test. 
Distribution normality for continuous variables 
was performed by Levene’s test. Continuous vari-
ables with normal distribution were expressed as 
mean ± standard deviation (SD) and those without 
normal distribution were expressed as median and 
25thand 75th percentiles. Group comparison of con-
tinuous variables was performed by Student’s t-
test and Mann-Whitney test, according to distribu-
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Results
According to the IDF defi nition of MetS, 68% of a 
total of 316 subjects involved in the study (Table 1) 
were aff ected by MetS. As expected, there were 
signifi cant diff erences in the concentrations of glu-
cose and HDL-cholesterol, as well as in waist cir-
cumference values and the frequency of hyperten-
sion between MetS(-) and MetS(+) groups. Addi-
tionally, the frequency of smokers and the concen-
trations of CRP were signifi cantly higher in MetS(+) 
subjects. There was no diff erence in the frequen-
cies of FABP2 Ala54Thr genotypes between the 
studied groups. The genotype frequencies for Ala/
Ala, Ala/Thr and Thr/Thr genotype were 60, 36 and 
6 in MetS(-), and 131, 70 and 13 in MetS(+), respec-
tively. Observed genotype frequencies of the 
FABP2 gene polymorphism were in Hardy-Wein-
berg equilibrium in both subjects’ groups. Ala/Ala 
genotype was considered to be the subgroup of 
Thr54 non-carriers, while heterozygous Ala/Thr 
and homozygous Thr/Thr genotypes were consid-
ered as subgroup of Thr54 carriers. Table 2 pres-
ents biochemical and anthropometric data for two 
genotype subgroups, separately for groups with 
and without MetS. Signifi cant diff erence was ob-
served for lipid concentrations between carriers 
and non carriers in MetS(+) subjects. The results of 
Mann-Whitney test showed that triglyceride con-
centration was signifi cantly lower (P = 0.050) in 
whole group, while genderwise the diff erence was 
evident only in female subjects (P = 0.020). T-test 
showed that mean HDL cholesterol concentrations 




N = 102 P OR
Gender, male (N, ratio) 95 (0.44) 45 (0.44) 0.963
Smoking (N, ratio) 51(0.24) 12 (0.12) 0.018
Hypertension (N, ratio) 197 (0.70) 86 (0.30) 0.024
FABP2 54 non-carrier (N, ratio) 131 (0.69) 60 (0.31) 0.777 1.0
FABP2 54Thr-carrier (N, ratio) 83 (0.66) 42 (0.34) 0.91 (0.56, 1.46)
FABP 2 - Allele A (N) 96 48 0.777 (P=0.684)
FABP 2 - Allele G (N) 332 156
Age (yrs) 77.6±4.2 78.8±4.7 0.031
Cholesterol (mmol/L) 5.43±1.21 5.42±1.00 0.897
HDL-cholesterol (mmol/L) 1.10±0.32 1.49±0.42 <0.001
LDL-cholesterol (mmol/L) 3.44±1.11 3.38±1.01 0.659
Proteins (g/L) 72.2±5.8 72.1±5.2 0.880
Waist circumference (cm) 103±10 94±17 0.039
BMI (kg/m2) 29.4±3.44 26.6±3.7 <0.001
Mean arterial pressure (mmHg) 108±11 109±12 0.616
Glucose (mmol/L) 6.00 (5.40-7.90) 5.00 (4.50-5.40) <0.001
Triglycerides (mmol/L) 1.87 (1.23-2.38) 1.16 (0.88-1.39) <0.001
CRP (g/L) 2.54 (1.50-5.07) 1.82 (1.13-3.48) 0.008
The frequencies of categorical variables were tested with Pearson chi-square test. Comparison of continuous variables between two subject 
groups was done using Student’s T-test for age, lipids, proteins, waist circumference, BMI and mean arterial pressure. Data were expressed as 
mean ± SD or median (interquartile range). Mann-Whitney test was used for comparison of triglycerides, glucose and CRP between two subjects 
groups. Data were expressed as median and 25th & 75th percentile.
BMI - body mass index; CRP – C-reactive protein; OR – odds ratio.
TABLE 1. Characteristics of study subjects according to metabolic syndrome presence.
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N-total=131 N-total=83 N-total=59 N-total=43
N-men=54 N-men=41 N-men=24 N-men=21
N-women=77 N-women=42 N-women=35 N-women=22
Cholesterol
(mmol/L)
T 5.47±1.21 5.38±1.21 0.620 5.50±1.05 5.31±0.93 0.363
M 5.14±1.14 4.99±1.17 0.524 5.09±1.05 5.01±0.64 0.799
W 5.70±1.21 5.77±1.14 0.753 5.78±0.97 5.60±1.09 0.508
HDL-cholesterol
(mmol/L)
T 1.04±0.31 1.19±0.33 0.001 1.50±0.42 1.48±0.42 0.685
M 0.98±0.29 1.10±0.29 0.039 1.36±0.47 1.42±0.50 0.688
W 1.08±0.31 1.26±0.34 0.004 1.61±0.35 1.53±0.33 0.378
LDL-cholesterol
(mmol/L)
T 3.45±1.17 3.43±1.03 0.888 3.43±1.07 3.32±0.95 0.606
M 3.19±1.29 3.17±1.07 0.928 3.15±1.11 3.10±0.81 0.854
W 3.63±1.05 3.68±0.93 0.783 3.61±1.01 3.54±1.04 0.770
Proteins (g/L)
T 72.6±5.6 71.5±5.9 0.199 72.2±5.13 71.9±5.31 0.793
M 73.3±4.8 71.2±5.9 0.094 72.2±6.14 71.6±4.00 0.815




T 103±9 102±11 0.851 93±15 94±20 0.722
M 106±8 104±11 0.439 100±13 102±24 0.693
W 100±9 100±12 0.989 88±13 86±12 0.605
BMI (kg/m2)
T 29.4±3.4 29.2±3.50 0.720 26.6±3.81 26.6±3.45 0.945
M 28.8±3.0 28.5±3.0 0.671 26.8±3.50 26.0±2.90 0.462




T 107±10 110±12 0.082 110±13 109±12 0.492
M 108±11 110±14 0.282 106±11 109±12 0.553
W 108±10 111±10 0.165 113±13 109±12 0.221
Glucose
(mmol/L)
T 6.10 (5.30-7.95) 5.90 (5.40-7.85) 0.724 5.00 (4.63-5.30) 5.00 (4.45-5.50) 0.925
M 6.10 (5.40-7.85) 6.10 (5.55-8.80) 0.371 5.00 (4.80-5.30) 4.85 (4.35-5.38) 0.612
W 6.10 (5.20-8.33) 5.85 (5.23-7.68) 0.675 5.00 (4.60-5.35) 5.05 (4.43-5.83) 0.614
Triglycerides
(mmol/L)
T 1.96 (1.39-2.48) 1.68 (1.09-2.15) 0.005 1.17 (0.93-1.43) 1.09 (0.82-1.35) 0.327
M 1.66 (1.11-2.41) 1.33 (0.97-2.15) 0.144 1.19 (0.99-1.52) 1.05 (0.70-1.41) 0.179
W 2.05 (1.52-2.59) 1.74 (1.29-2.17) 0.020 1.12 (0.92-1.39) 1.25 (0.88-1.34) 0.961
CRP (g/L)
T 2.56 (1.50-5.50) 2.46 (1.47-4.77) 0.405 1.89 (1.12-3.48) 1.79 (1.16-3.50) 0.952
M 2.51 (1.86-5.43) 2.27 (1.64-4.17) 0.392 1.50 (0.99-3.52) 1.77 (0.90-4.08) 0.715
W 2.66 (1.32-5.70) 3.07 (0.88-5.46) 0.753 2.00 (1.12-3.51) 1.79 (1.16-3.28) 0.842
The association of genotypes - carriers of 54Thr allele and blood and anthropometrics parameters was performed using t-test or 
Mann-Whitney-test based on distribution normality.
T - total; M - men; W – women.
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group (P = 0.001), and for both genders (men P = 
0.039; women P = 0.004) as compared to Thr54 
non-carriers. There is no any diff erence between 
carriers and non-carriers in subjects without MetS 
for neither of parameters tested.
Discussion
The results of the present study showed that there 
is no signifi cant diff erence in the frequency of 
FABP2 Ala54Thr polymorphism between the sub-
jects with and without MetS according to the IDF 
criteria. As expected, there is a signifi cant diff er-
ence in lipid parameters between these subjects. 
Signifi cantly lower TGs and higher HDL-cholesterol 
mean concentrations in carriers of 54Thr allele as 
compared to non-carriers indicate that the 54Thr 
allele might have a protective role in subjects with 
MetS after an overnight fast. Gender and age as 
covariates showed a statistically signifi cant but 
clinically irrelevant eff ect of the Thr54 carriers on 
total and LDL-cholesterol concentrations, as well 
as on waist circumference and BMI levels.
There are many confl icting conclusions in investi-
gations of Ala54Thr polymorphism and lipid pro-
fi le. The reduction in plasma triglyceride level in 
the carriers of Thr allele was found in sixteen 
healthy postmenopausal women in a cross-over 
designed feeding trial in which these women were 
undergoing a high-fat diet (29). The lowest values 
for triglyceride-rich lipoprotein (TRL) cholesterol 
and TRL phospholipids were found in women ho-
mozygous for the Thr54-encoding allele, whereas 
the highest values were found in men homozy-
gous for the Thr54-encoding allele (30). This study 
was designed as a clinical trial involving subjects 
who were subject to a low-fat American Heart As-
sociation–type diet. A Spanish cross-sectional 
study did not fi nd any diff erence in anthropomet-
ric and lipid parameters between genotypes in 
subjects with or without MetS (19). The results of 
our study also showed the lack of association be-
tween the Thr54/Ala54 and Thr54/Thr54 FABP2 
genotypes and MS.
The meta-analysis that included investigations 
published before June 2009 showed the opposite 
results for lipid parameters in the fasting state (18). 
This meta-analysis involved adults of at least 18 
years of age, from diff erent populations, and with 
diff erent health disorders. Several studies with 
obese subjects reported that 54Thr allele was not 
associated with higher TGs or lower HDL-choles-
terol fasting concentrations. However, the general 
conclusion was that 54Thr allele was associated 
with higher concentrations of TGs and lower con-
centrations of HDL-cholesterol, which is contradic-
tory to our results.
FABP2 Ala54Thr polymorphism may aff ect lipid lev-
els depending on the composition of dietary in-
take. Chamberlain et al. (17) concluded that limit-
ing dietary saturated fat intake may be particularly 
important among the carriers of the A allele of 
FABP2 among young adults. They did not fi nd any 
diff erence in lipid profi les in the fasting state. A 
large Japanese case-control study showed that 
Thr54 represented a risk factor for myocardial in-
farction in subjects with MetS, although it was re-
lated to reduced fasting glucose and total choles-
terol concentrations (31).
In vitro studies showed that FABP2 is responsible 
for postprandial transport and partitioning of 
long-chain free fatty acids (FFA) toward TG synthe-
sis (32). Overexpression of FABP2 in HIEC-6 cells 
also showed a minor eff ect on monounsaturated 
fatty acid oxidation. THr54 isoform of FABP2 has 
higher binding affi  nity of substrate oleate and 
arachidonate than Ala 54 isoform (33).
It can be expected that polymorphisms of FABP2 
will not aff ect fasting lipid values because they are 
responsible for postprandial fatty acid transport. 
General conclusion might be that literature data 
are inconsistent and depend on study designs, 
number of subjects, age, ethnicity, clinical trials 
etc.
There are several limitations to this investigation. 
The study included subjects over 70 years of age 
and the frequency of MetS is higher in older than 
in younger subjects. Furthermore, previous follow-
ups lack data and this might explain dyslipidemia 
induced by Ala54Thr polymorphism. Determina-
tion of free fatty acids (FFA) and composition of 
FFA also might be useful in explaining the above 
mentioned polymorphism association with MetS 
because of diff erent substrate affi  nity of genetic 
variants (14). The lack of data on lipid concentra-
tions in postprandial state and on subjects who re-
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ceived statin therapy represents an additional 
weakness of this study. However, an added value 
of this study is the fact that this is the fi rst such 
study on the eff ects of FABP2 Ala54Thr polymor-
phism in Croatian subjects. Results of this study 
might contribute to the understanding of patho-
phisiology of dyslipidemia and MetS, as well as of 
other related multifactorial disorders.
In conclusion, there is evidence that FABP2 genetic 
variations alter triglyceride and HDL-cholesterol 
concentrations in elderly subjects with MetS. 
These genetic variations might be useful markers 
for understanding dyslipidemia in MetS.
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Polimorfi zam gena FABP 2 i metabolički sindrom u starijih osoba hrvatskog 
porijekla
Sažetak
Uvod: Metabolički sindrom (MetS) je multifaktorijelni poremećaj kod kojeg dislipidemija ima ključnu ulogu. Protein-nosač masnih kiselina 2 
(FABP 2) je odgovoran za prijenos slobodnih masnih kiselina u stanicama crijevnog endotela. Genske varijante mogu utjecati na promjene kon-
centracija lipida u plazmi kao i na unutarstanični prijenos lipida. Cilj ovog istraživanja je ispitati povezanost polimorfi zma Ala54Thr gena FABP2 
i metaboličkog sindroma, antropometrijskih i biokemijskih parametara u starijih osoba.
Materijali i metode: U istraživanje je uključeno 140 muškaraca i 176 žena iznad 70 godina starosti. Koncentracije glukoze, lipidnih parameta-
ra, ukupnih proteina i C-reaktivnog proteina određene su standardnim metodama u uzorcima seruma uzetim natašte. Prisutnost (MetS(+)) ili 
odsutnost (MetS(-)) MetS su određene na temelju kriterija Međunarodne federacije za šećernu bolest. Genski polimorfi zam FABP2, Ala 54Thr 
(rs1799883) je genotipiziran metodom PCR-RFLP.
Rezultati: Učestalost genotipova Ala/Ala, Ala/Thr i Thr/Thr bila je redom 60, 36 i 6 kod MetS(-) ispitanika, te 131, 70 i 13 kod MetS(+) ispitanika, 
bez statistički značajne razlike (P = 0,567). Genotip Ala/Ala predstavlja skupinu nenositelja dok su genotipovi Ala/Thr i Thr/Thr nositelji Thr54 
alela. Median koncentracije triglicerida je bio značajno niži kod Thr-nositelja u cjelovitoj MetS(+) skupini (P = 0,050), bez značajne razlike kod 
muškaraca (P = 0,144), ali sa značajnom razlikom kod žena s MetS (P = 0,020). T-test je pokazao da je srednja vrijednost koncentracije HDL-kole-
sterola Thr54-nositelja značajno viša u cjelovitoj skupini s MetS (P = 0,001) i to kod oba spola (muškarci P = 0,039; žene P = 0,004).
Zaključci: Genski polimorfi zam FABP2 je povezan s nižom koncentracijom triglicerida te višom koncentracijom HDL-kolesterola kod starije popu-
lacije s MetS. Ova genska varijanta može biti koristan biljeg za razumijevanje dislipidemije kod MetS.
Ključne riječi: proteini-nosači masnih kiselina (FABPs); genski polimorfi zam FABP2; metabolički sindrom
